The global hemophilia treatment market is on a strong growth trajectory, with projections indicating a rise from USD 12.1 billion in 2024 to a remarkable USD 18.7 billion by 2034. This growth, driven ...

Closer to market is Sobi-partnered efanesoctocog alfa (also known as BIVV001), an engineered recombinant Factor VIII designed to sustain high protection from bleeds in people with haemophilia A ...

Marstacimab will be launched as Hympavzi to treat haemophilia A without factor VIII inhibitors and haemophilia ... as well as its range of recombinant clotting factor replacement products.

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII expression, with factor VIII activity correlating to vector copy number in ...

1B). These plasmids were expressed in Lec 3.2.8.1 CHO cells and the recombinant proteins purified and analyzed by gel electrophoresis showing the expected band sizes after reduction (Fig. 1C). Without ...

Medical genetics involves the application of genetics to medical care, including research on the causes and inheritance of genetic disorders, and their diagnosis and management. A rare variant ...